These findings suggest that measuring serum levels of TGF-β1 and VEGF may provide a non-invasive means of identifying patients with high-risk bladder cancer and offer insight into the tumor’s inflammatory and angiogenic state [104]. This evidence concerns the gene VEGFA and urinary bladder cancer.